Leo Pharma to terminate up to 150 R&D jobs
10–15 percent of positions in Leo Pharma’s research and development unit will be trimmed as a consequence of the announced restructuring of the company. A new strategy is to motivate the remaining R&D team, says the company’s head of global research and development.
by ULRICH QUISTGAARD, translated by daniel pedersen
Dermatology firm Leo Pharma is closing between 100 and 150 jobs in its research and development unit, which currently counts around 1,000 employees.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Layoffs and restructuring will prepare Leo Pharma for IPO
For subscribers
Leo Pharma poaches Novo Nordisk VP to lead US division
For subscribers
